monitored daily. The following determinations were performed at frequent intervals: complete blood cell count with differential counts, Coombs' test, urinalysis, glutamic oxaloacetic and pyruvic transaminases, bilirubin, alkaline phosphatase, electrolytes, glucose, creatinine and blood urea. Appropriate cultures were obtained from all patients before and, when possible, during and after termination of therapy. In respiratory tract infections, tracheal aspirations were performed to obtain specimens free of oropharyngeal flora but no follow-up cultures were possible from these patients.
Susceptibility Testing
Minimum inhibitory concentrations were determined on the clinical isolates against cefuroxime, cefoxitin, cefamandole, cephalothin and cefazolin by the agar or broth dilution technique (Ericsson & Sherris 1971) . RESULTS 
Efficacy
The therapy was evaluated by 2 principal methods, clinical outcome and bacteriological outcome, and both are summarized in Table 1 . Table 2 gives details of patients with lower respiratory tract infection. Of the 12 patients, 10 were clinically cured. One patient (No. 4) died of underlying disease although the infection was under control. Patient No. 3, who was given cefuroxime in combination with 80 mg of gentamicin, had a super-infection with Pseudomonas aruginosa and the therapy was changed to carbenicillin plus tobramycin. Patient No. 10, an alcoholic, had an anxrobic pneumonia, which failed to respond to 2250 mg of cefuroxime/day. He was put on 900 mg of clindamycin/day and the pneumonia was cured. Patient No. I had an infection with Proteus vulgaris, Citrobacter and Escherichia coli (isolated from transtracheal aspirate) and was successfully treated although the P. vulgoris strain was resistant to cephalothin, cefazolin and cefamandole (minimum inhibitory concentrations >32 jug/ml The present study was undertaken to determine the clinical efficacy, patient tolerance and safety of cefuroxime in the therapy of infections caused by susceptible organisms.
Respiratory Tract Infections

Materials and Methods
Patients were hospitalized at the Centre for Internal Medicine of the University Hospital, Frankfurt-on-Main. fn all cases clinical findings and either prior culture or Gram stained material suggested infection with bacteria likely to be susceptible to the cephalosporins or shown to be susceptible to cefuroxime itself. Consent was obtained from the patients or their relatives.
Duration of Therapy and Pathology
Twenty-eight patients (23 male and 5 female) were treated with cefuroxime. The age range was 21-74 years. The duration of therapy was 5-21 days. Twenty-six patients received 2250 mg/day. Two were given 4500 mg/day. Twelve patients had respiratory tract, 7 had urinary tract and 4 had soft tissue infection. One had gonorrhea and 4 had bacternmia. No pathogenic organisms were cultured in 4 patients despite clinical signs of infection. Administration and Monitoring Cefuroxime was given i.v. at doses of 750 mg or 1.5 g (2 patients) within 3 min. Doses were administered every 8 h. Possible toxicity was (Table 3 ). Two patients (No. 13 and 15) had a relapse showing the original bacteria the day after the therapy was stopped. Patient No. 12 with carcinoma of the urinary bladder, chronic pyelonephritis and hepatitis, was readmitted 8 weeks later with an elevated temperature. Blood and urine cultures yielded the initial Proteus mirabilis strain still sensitive to cefuroxime. Three of the infections were considered to be resistant to cephalothin and cefazolin, 2 were also resistant to cefamandole and gentamicin, showing no zone of inhibition on DST agar.
Bacterwemia
In only 3 of the 4 patients with bacterwmia could the pathogen be cultured (Table 4 ). In patient No. 21, clinical signs of bacteramia were present, but the organism could not be cultured from blood. Clinical cure was achieved in 3 patients.
Patient No. 23 who had developed a Klebsiella pneumoniac bactermmia under therapy with cefazolin plus gentamicin, died on the fifth day after starting therapy with cefuroxime. The K. pneumoniwe strain, which was resistant to cephalothin, cefazolin and cefamandole, was eliminated with cefuroxime.
Miscellaneous Infections
All of the patients with soft tissue infection and the I patient with gonorrhaea were clinically and bacteriologically cured (Table 5 ).
Adverse Reactions and Patient Tolerance
Adverse reactions definitely related to cefuroxime were seen in only 2 patients (Table 6 ). In I patient we saw a transient eosinophilia. In another patient with chronic pyelonephritis, cardiac insufficiency and a pace maker, who was treated for a P. mirabilis urinary tract infection resistant to gentamicin, cephalothin, cefazolin and cefamandole, there was a rise in blood urea and creatinine. In those patients with elevated serum glutamic oxaloacetic and glutamic pyruvic transaminases the elevation could be traced back Cefuroxime to the underlying condition such as hepatitis or liver metastasis. The i.v. application of cefuroxime was well tolerated by all the patients. There was no incidence of phlebitis.
Discussion
In vitro studies have shown cefuroxime to be active against both Gram positive and negative bacteria (Eykyn et at. 1976 , Verbist 1976 including cephalothin resistant organisms such as indole positive Proteus. Susceptibility testing of isolates from our patients supports the finding that cefuroxime has enhanced activity against cephalothin susceptible Gram negative organisms and good activity against cephalothin resistant organisms (Shah 1976).
Like penicillin, cephalosporins are relatively free of undesirable side effects and toxicity. In the present study, cefuroxime related adverse reactions were seen in only 2 patients: a transient eosinophilia and rise in blood urea and creatine. Such side effects have been described with cephalosporins (Moellering & Schwartz 1976) .
Cefuroxime was well tolerated by all the patients. Phlebitis caused by cephalosporins has been reported with an incidence of approximately 30 0. In the present study none was encountered which might be due to the mode of application. Twenty-five patients without a central venous catheter were subjected to 3 venous punctures daily.
A broad experience of cefuroxime therapy in a variety of infections in seriously ill patients was obtained in this study. Some of them had infections due to multiresistant organisms. Cefuroxime was effective in eradicating infection in the majority of patients and appeared relatively nontoxic. In I patient with anerobic pneumonia there was clinical and bacteriological failure. This suggests the need for further studies on the susceptibility of anerobes to cefuroxime and possibly on the value of higher dosages in such conditions. In an open study of 140 patients they had compared 750 mg against 1 g three times daily in severe respiratory infection. Assignment of patients was according to the physician's choice and not strictly random but 1 g three times daily had seemed superior. However, a subsequent double blind trial in 80 patients had shown no difference between 750 mg and 1 g three times daily, and the lower dose seemed sufficient even in the most severe respiratory infection. There was no difference in cefuroxime sputum levels between 750 mg and 1 g either, although the significance of sputum levels was debatable.
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Dr J M Verstraeten (Ghent) said that after 10 days of treatment some of his patients had relapsed 5 days later. Most were elderly patients with respiratory tract disease due to Streptococci or Hwemophilus.
Professor De Sandre said that he had observed no such relapse.
Dr E S Snell (Greeiford) asked Dr Shah why, in a patient with pyelonephritis, cardiac failure and a pace maker he had attributed the rise of blood urea to the drug rather than any other factor. Dr Shah said that the patient's blood urea and creatinine prior to therapy with cefuroxime had been normal and this had been the only drug that the patient was receiving. Indeed values did not return to normal during the 2-week follow up period between stopping the therapy and the patient leaving hospital. The patient was not in cardiac failure, his underlying condition was cardiac insufficiency.
Dr Sterner (Chairman) asked Professor de Sandre to elaborate on the results of blood culture in septicemia cases.
Professor De Sandre said that there was only I case of septicxmia in his personal group of 27 patients. Three patients in other centres were successfully treated and in 4 there was a partial resolution of the infection. The only case in which the micro-organism was detected in the blood was where the condition was due to Staphylococcus.
